ArticleInternational journal of molecular sciences2023
BRAF-AXL-PD-L1 Signaling Axis as a Possible Biological Marker for RAI Treatment in the Thyroid Cancer ATA Intermediate Risk Category.
Article in International journal of molecular sciences, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
23 citing papers in PubMed, 1 synthesis or guideline pooled it, 17 citations in OpenAlex.
- DICER1 alterations in thyroid lesions: a systematic review and meta-analysis with clinicopathologic implications.Virchows Archiv : an international journal of pathology · 2026Pooled it
- PD-L1 in Merkel Cell Carcinoma: From Tumor Microenvironment to Pathological Interpretation.International journal of molecular sciences · 2026Review
- EnhancingQuantitative imaging in medicine and surgery · 2026Article
- Morphologic, Immunohistochemical, and Molecular Features of Laser-Ablated Thyroid Nodules: Diagnostic Pitfalls and Differential Diagnosis with Thyroid Carcinoma.International journal of molecular sciences · 2026Article
- Article
- Prognostic Significance of Dynamic Free T3 Changes in Critically Ill Patients.Clinics and practice · 2026Article
- Osteopontin-4 (OPN-4) Suppresses Tumor Progression Features Whilst Sensitizing c643 Anaplastic Thyroid Cells to Sorafenib.Biomedicines · 2026Article
- The shifting paradigm of programmed cell death ligand 1 (PD-L1) in anaplastic thyroid carcinoma: from pathology to clinical practice.Virchows Archiv : an international journal of pathology · 2026Review
- Detection of TERT Promoter Mutations in Papillary Thyroid Carcinoma Using Droplet Digital PCR and Their Association with Aggressive Tumor Features.International journal of molecular sciences · 2026Article
- The Diagnostic and Prognostic Role of CombinedInternational journal of molecular sciences · 2026Review
- Preoperative Circulating Tumor Cells (CTCs) Positivity is Associated with Lymph Node Metastasis in Patients with Unifocal Papillary Thyroid Microcarcinoma (PTMC).International journal of general medicine · 2026Article
- Case Report: Evolution of a BRAF V600E-mutant papillary thyroid carcinoma from latissimus dorsi metastasis and squamous transformation to PD-L1 upregulation and effective immunotherapy.Frontiers in immunology · 2026Article
- Improving Non-Invasive Prediction of Thyroid Nodule Malignancy: A Machine Learning-Based Clinical Approach.Cancer management and research · 2026Article
- The relationship between the extent of extrathyroidal extension and lymph node metastasis based on propensity score matching analysis.Gland surgery · 2025Article
- A predictive model using platelets and neutrophil-to-lymphocyte ratio for the number of lymph node metastases in papillary thyroid carcinoma: a retrospective analysis.Gland surgery · 2025Article
- Safety and Efficacy of Immune Checkpoint Inhibitors in Human Immunodeficiency Virus-Associated Cancer: A Systematic Scoping Review.Diseases (Basel, Switzerland) · 2025Review
- Proteolysis of TAM receptors in autoimmune diseases and cancer: what does it say to us?Cell death & disease · 2025Review
- AXL: shapers of tumor progression and immunosuppressive microenvironments.Molecular cancer · 2025Review
- Histologic Evaluation of Thyroid Nodules Treated with Thermal Ablation: An Institutional Experience.International journal of molecular sciences · 2024Article
- The Role of Body Mass Index (BMI) in Differentiated Thyroid Cancer: A Potential Prognostic Factor?Biomedicines · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors at 3 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The use of radioiodine therapy (RIT) is debated in intermediate-risk differentiated thyroid cancer (DTC) patients. The understanding of the molecular mechanisms involved in the pathogenesis of DTC can be useful to refine patient selection for RIT. We analyzed the mutational status of BRAF, RAS, TERT, PIK3 and RET, and the expression of PD-L1 (as a CPS score), the NIS and AXL genes and the tumor-infiltrating lymphocytes (TIL, as the CD4/CD8 ratio), in the tumor tissue in a cohort of forty-six ATA intermediate-risk patients, homogeneously treated with surgery and RIT. We found a significant correlation between BRAF mutations and a less than excellent (LER, according to 2015 ATA classification) response to RIT treatment (
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.